Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChaperone Combo vs Humalog Mix25 and Humalog+Lantus in T2DM
NCT02915250Phase 1Completed
- Sponsor
- Adocia
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BioChaperone glargine lispro in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Adocia. Primary endpoint: Delta Area Under the Blood Glucose Concentration-Time Curve 0-2h. Started Oct 2016; status: completed.
02
Drugs
BioChaperone glargine lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02915250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915250.